keyword
MENU ▼
Read by QxMD icon Read
search

Second lung cancer

keyword
https://www.readbyqxmd.com/read/28346656/7-year-follow-up-after-stereotactic-ablative-radiotherapy-for-patients-with-stage-i-non-small-cell-lung-cancer-results-of-a-phase-2-clinical-trial
#1
Bing Sun, Eric D Brooks, Ritsuko U Komaki, Zhongxing Liao, Melenda D Jeter, Mary F McAleer, Pamela K Allen, Peter A Balter, James D Welsh, Michael S O'Reilly, Daniel Gomez, Stephen M Hahn, Jack A Roth, Reza J Mehran, John V Heymach, Joe Y Chang
BACKGROUND: The authors evaluated the efficacy, patterns of failure, and toxicity of stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical stage I non-small cell lung cancer (NSCLC) in a prospective clinical trial with 7 years of follow-up. Clinical staging was performed according to the seventh edition of the American Joint Committee on Cancer TNM staging system. METHODS: Eligible patients with histologically confirmed NSCLC of clinical stage I as determined using positron emission tomography staging were treated with SABR (50 grays in 4 fractions)...
March 27, 2017: Cancer
https://www.readbyqxmd.com/read/28344664/current-understanding-and-approach-to-well-differentiated-lung-neuroendocrine-tumors-an-update-on-classification-and-management
#2
REVIEW
Talal Hilal
Neuroendocrine tumors (NETs) are rare neoplasms that can arise from any tissue. They are classified based on embryonic gut derivative (i.e. foregut, midgut and hindgut) with midgut tumors being the most common (e.g. gastrointestinal NET). The second most common category of NETs is that which arises from the lung. In fact, 25% of primary lung cancers are NETs, including small cell lung cancer (SCLC), which comprises 20% of all lung cancers. The remaining 5% are large cell neuroendocrine cancer (LCNEC, 3%), typical carcinoids (TCs, 1...
March 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28338643/geographical-correlations-between-indoor-radon-concentration-and-risks-of-lung-cancer-non-hodgkin-s-lymphoma-and-leukemia-during-1999-2008-in-korea
#3
Mina Ha, Seung-Sik Hwang, Sungchan Kang, No-Wook Park, Byung-Uck Chang, Yongjae Kim
Indoor radon is the second most important risk factor for lung cancer and may also be a risk factor for hematopoietic cancers, particularly in children and adolescents. The present study measured indoor radon concentration nationwide at 5553 points during 1989-2009 and spatially interpolated using lognormal kriging. The incidences of lung cancer, non-Hodgkin's lymphoma (NHL), and leukemia, stratified by sex and five-year age groups in each of the 234 administrative regions in the country during 1999-2008, were obtained from the National Cancer Registry and used to calculate the standardized incidence ratios...
March 24, 2017: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/28338430/trends-of-second-primary-malignancy-in-patients-with-thyroid-cancer-a-population-based-cohort-study-in-israel
#4
Elena Izkhakov, Micha Barchana, Irena Liphshiz, Barbara Silverman, Naftali Stern, Lital Keinan-Boker
BACKGROUND: Thyroid cancer (TC) is the most common endocrine malignancy. TC patients have a good prognosis and a low disease-related mortality rate. Since the patients are often young, they may be at a higher risk for a second primary malignancy (SPM). We sought to determine the incidence, risk and types of SPM between 1980-2011, and to assess SPM trends over time among Israeli TC patients. METHODS: Data were derived from the Israel National Cancer Registry. Primary TC patients diagnosed during 1980-2009 were followed-up for SPM incidence until December 31, 2011...
March 24, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28338376/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer
#5
Mirte Muller, Robert D Schouten, Cornedine J De Gooijer, Paul Baas
In the last years, a spectacular development of immunotherapeutic agents aimed at the PD-1/PD-L1 axis has taken place. This development of these checkpoint inhibitors has greatly influenced our approach to the treatment of lung cancer in first and second line. The limited toxicity profile and the ability to treat for prolonged periods, even in smokers, is a welcome expansion of the therapeutic arsenal of the oncologist. Areas Covered: This review highlights the results of recent clinical trials on pembrolizumab for the treatment of non-small cell lung cancer...
March 24, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28337378/in-vivo-growth-and-responses-to-treatment-of-renal-cell-carcinoma-in-different-environments
#6
Yahya Alhamhoom, Guisheng Zhang, Mingming Gao, Houjian Cai, Dexi Liu
Renal cell carcinoma is the most common type of kidney cancer in adults and is associated with poor prognosis. The hydrodynamic cell delivery technique was employed in this study to establish tumor growth in mouse lung, liver and kidneys. We demonstrate that Renca(Luc) cells exhibit different growth rates and responses to the cancer treatment of 5-florouracil and cytokine gene therapy when growing in different organs. The tumor growth rate was faster in the kidneys compared to that in the lung and liver. The liver is the second-best organ in support of tumor growth...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28337370/role-of-epidermal-growth-factor-receptor-in-lung-cancer-and-targeted-therapies
#7
REVIEW
Tie-Cheng Liu, Xin Jin, Yan Wang, Ke Wang
Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers (SCLC), have responded effectively to chemo-, radiation and adjuvant-therapies. Tumor removal through surgery also appeared as a good therapeutic strategy. However, these therapies demonstrated unfavourable side-effects, and hence novel drugs targeting lung cancer emerged essential. Activation of epidermal growth factor receptor (EGFR)-tyrosine kinases is a key reason for lung cancer progression...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28336778/the-predictive-value-of-early-in-treatment-fdg-pet-ct-response-to-chemotherapy-in-combination-with-bevacizumab-in-advanced-non-squamous-non-small-cell-lung-cancer
#8
Edwin A Usmanij, Tinatin Natroshvili, Johanna N H Timmer-Bonte, Wim J G Oyen, Miep A van der Drift, Johan Bussink, Lioe-Fee de Geus-Oei
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) is potentially applicable to predict response to chemotherapy in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Methods: In 25 patients with advanced non-squamous NSCLC, (18)F-FDG-PET/CT was performed before treatment and after two-weeks, at the end of the second week of first cycle carboplatin - paclitaxel and bevacizumab (CPB) treatment. Patients received up to a total of 4 cycles of CPB treatment...
March 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28335643/prospects-and-progress-of-atezolizumab-in-non-small-cell-lung-cancer
#9
Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan Sandler, Alexander Spira
Immunotherapy has recently come to the forefront of oncology treatment as a potential means of combating cancer by restoring the body's adaptive cancer-immunity cycle. Atezolizumab is a monoclonal antibody agent that specifically targets programmed death ligand 1 (PD-L1), a key molecule in the cancer-immunity pathway, to block binding to its receptors PD-1 and B7.1. Areas covered: This review covers the role of atezolizumab in the treatment of non-small-cell lung cancer (NSCLC). Several studies have reported promising efficacy in this indication...
March 24, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28332225/molecular-dynamics-validation-of-crizotinib-resistance-to-alk-mutations-l1196m-and-g1269a-and-identification-of-specific-inhibitors
#10
Nagasundaram Nagarajan, Carlton Ranjith Wilson Alphonse, Prakash Vincent Samuel Gnana, Rajesh Kannan Rajaretinam
Anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations. However, patients treated with these drugs invariably relapsed because of the development of new drug resistance mutations. In this study we explored the crizotinib resistance in the presence of ALK mutations L1196M and G1269A through molecular dynamics simulation studies...
March 23, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28326832/nintedanib-plus-docetaxel-as-second-line-therapy-in-patients-with-non-small-cell-lung-cancer-of-adenocarcinoma-histology-a-network-meta-analysis-vs-new-therapeutic-options
#11
Sanjay Popat, Anders Mellemgaard, Martin Reck, Claudia Hastedt, Ingolf Griebsch
PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1...
February 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28325254/egfr-inhibition-in-nsclc-new-findings%C3%A2-and-opened-questions
#12
REVIEW
Francesco Passiglia, Angela Listì, Marta Castiglia, Alessandro Perez, Sergio Rizzo, Viviana Bazan, Antonio Russo
The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients' outcomes...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28323493/microparticles-containing-erlotinib-loaded-solid-lipid-nanoparticles-for-treatment-of-non-small-cell-lung-cancer
#13
Zahra Bakhtiary, Jaleh Barar, Ayuob Aghanejad, Amir Ata Saei, Elhameh Nemati, Jafar Ezzati Nazhad Dolatabadi, Yadollah Omidi
Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18-21 of the epithelial growth factor receptor (EGFR) geneshowincreased kinase activity of EGFR. Hence, tyrosine kinase inhibitors (TKIs) such as erlotinib (ETB) havecommonly been used as the second line therapeutic option in metastatic NSCLC. While the ETB is available as an oral dosage form, the local delivery of this TKI to the diseased cells of the lung may ameliorate its therapeutic impacts. In the current study, we report on the development of ETB-loaded solid lipid nanoparticle (SLN) based formulation of dry powder inhaler (ETB-SLN DPI)...
March 21, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28322158/effect-and-mechanism-of-curcumin-on-ezh2-mir-101-regulatory-feedback-loop-in-multiple-myeloma
#14
Chuanqing Wu, Tuo Ruan, Weizhen Liu, Xiaojie Zhu, Juan Pan, Wen Lu, Chen Yan, Kaixiong Tao, Weikang Zhang, Chun Zhang
BACKGROUND: Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable. Therefore, it's urgent to find new drugs for treatment. Some experiments have shown that curcumin might have great potential in treating multiple myeloma, while the mechanism is still unknown. EZH2 and SUZ12 are the core proteins in PRC2 and their expression are increased in various human cancers, including the poor prognostic multiple myeloma. Meanwhile, the regulation of miRNAs and EZH2 has been demonstrated in other cancer researches, like lung cancer, pancreatic cancer, leukemia and so on...
March 17, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28321814/immunotherapy-in-nsclc-a-promising-and-revolutionary-weapon
#15
Christian Rolfo, Christian Caglevic, Mariacarmela Santarpia, Antonio Araujo, Elisa Giovannetti, Carolina Diaz Gallardo, Patrick Pauwels, Mauricio Mahave
Lung cancer is the leader malignancy worldwide accounting 1.5 millions of deaths every year. In the United States the 5 year-overall survival is less than 20% for all the newly diagnosed patients. Cisplatin-based cytotoxic chemotherapy for unresectable or metastatic NSCLC patients in the first line of treatment, and docetaxel in the second line, have achieved positive results but with limited benefit in overall survival. Targeted therapies for EGFR and ALK mutant patients have showed better results when compared with chemotherapy, nevertheless most of patients will fail and need to be treated with chemotherapy if they still have a good performance status...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28320555/a-population-based-statistical-model-for-daily-geometric-variations-in-the-thorax
#16
Yenny Z Szeto, Marnix G Witte, Marcel van Herk, Jan-Jakob Sonke
PURPOSE: To develop a population based statistical model of the systematic interfraction geometric variations between the planning CT and first treatment week of lung cancer patients for inclusion as uncertainty term in future probabilistic planning. MATERIALS AND METHODS: Deformable image registrations between the planning CT and first week CBCTs of 235 lung cancer patients were used to generate deformation vector fields (DVFs) representing the geometric variations of lung cancer patients...
March 17, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28319436/estimating-the-risks-of-breast-cancer-radiotherapy-evidence-from-modern-radiation-doses-to-the-lungs-and-heart-and-from-previous-randomized-trials
#17
Carolyn Taylor, Candace Correa, Frances K Duane, Marianne C Aznar, Stewart J Anderson, Jonas Bergh, David Dodwell, Marianne Ewertz, Richard Gray, Reshma Jagsi, Lori Pierce, Kathleen I Pritchard, Sandra Swain, Zhe Wang, Yaochen Wang, Tim Whelan, Richard Peto, Paul McGale
Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality...
March 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28314541/risk-of-subsequent-primary-kidney-cancer-after-another-malignancy-a-population-based-study
#18
Omar Abdel-Rahman
BACKGROUND: Population-based data on the development of kidney cancer as a second malignant neoplasm following the diagnosis of other common malignancies are rare. This clinical scenario has been evaluated within the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: The SEER-9 database (1973-2013) was queried using the SEER*Stat program to determine the standardized incidence ratios (SIRs) of kidney cancer development following each one of 10 common invasive malignancies (colorectal, breast, prostate, lung, thyroid, corpus uteri, urinary bladder, kidney/renal pelvis, cutaneous melanoma, and non-Hodgkin lymphoma)...
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28314326/impact-of-maintenance-therapy-for-patients-with-non-small-cell-lung-cancer-in-a-real-world-setting
#19
Kiyotaka Yoh, Yasushi Goto, Yoichi Naito, Kazuma Kishi, Kiyoshi Mori, Katsuyuki Hotta, Yukio Hosomi, Kazuhiko Yamada, Chiharu Tanai, Yoshio Tomizawa, Akira Inoue, Yoshinori Hasegawa, Makoto Nishio, Yasuo Ohashi, Hideo Kunitoh
BACKGROUND: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting. PATIENTS AND METHODS: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up. RESULTS: Between 2010 and 2011, a total of 864 patients were enrolled in this study...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314312/surgical-resection-for-pulmonary-metastasis-from-pancreatic-and-biliary-tract-cancer
#20
Tetsuzo Tagawa, Kensaku Ito, Kengo Fukuzawa, Tatsuro Okamoto, Atsuro Yoshimura, Takahide Kawasaki, Takashi Masuda, Kentaro Iwaki, Takahiro Terashi, Masahiro Okamoto, Akio Shiromizu, Akira Motohiro, Yoshihiko Maehara
AIM: To determine the efficacy of pulmonary metastasectomy for pancreatic and biliary tract cancer. PATIENTS AND METHODS: Ten patients who underwent therapeutic pulmonary metastasectomy after resection for pancreatic and biliary tract cancer at our Institution from 2006 to 2016 were retrospectively evaluated. RESULTS: The primary site was the pancreas in four patients and biliary tract in six. Nine patients had single metastasis, and one patient had bilateral multiple metastases...
March 2017: Anticancer Research
keyword
keyword
89876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"